Exsilio Therapeutics emerged from stealth mode on June 25, 2024, with $82 million from a series A financing that was co-led by Novartis Venture Fund and Delos Capital. The company plans to use naturally occurring, mobile genetic elements to integrate therapeutic genes at a defined location in the genome, making it safer than random integration, which can cause tumor formation.

Nexsen Biotech Pty Ltd. developed a rapid diagnostic test for Group B Streptococcus, a highly prevalent and potentially fatal bacteria that is the single largest maternal health problem faced by pregnant mothers.

Exsilio Therapeutics emerged from stealth mode on June 25, 2024, with $82 million from a series A financing that was co-led by Novartis Venture Fund and Delos Capital. The company plans to use naturally occurring, mobile genetic elements to integrate therapeutic genes at a defined location in the genome, making it safer than random integration, which can cause tumor formation.

Newco Yellowstone Biosciences Ltd. has been formed to develop soluble bispecific T-cell receptors against a novel class of tumor-specific antigens it has discovered in leukemia patients who were cured by a donor stem cell transplant. The company has proprietary access to a biobank of over 10,000 samples from more than 3,000 acute myeloid leukemia (AML) patients. A small number of these patients were cured by an allogeneic bone marrow transplant, whilst unusually, having no sign of graft-vs.-host disease.

On the heels of a $7 million seed round, Singapore-based medical technology startup Thrixen Pte Ltd. is accelerating development of its diagnostic technology platform that has the potential to perform multiplex diagnostic tests at the point of care.

Hagar Non-invasive Glucose Monitoring Ltd.’s non-invasive radiofrequency (RF) glucose monitor, Gwave, demonstrated high concordance with both venous and capillary glucose measurements in a study published in Diabetes Technology & Therapeutics.

Fledgling biotech Ternarx Pty Ltd. has emerged from stealth mode and is the first of its kind in Australia to develop targeted protein degrader technology to destroy disease-causing proteins that cannot be targeted by conventional drugs. The Melbourne-based company will initially develop targeted protein degraders against currently undrugged transcription factors in cancers with significant unmet need, starting with neuroblastoma and prostate cancer.

Marea Therapeutics came out of stealth mode on June 18, after raising a combined $190 million through its series A and B financings. The series A round was led by Third Rock Ventures, and the series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and Venbio.

The first patenting from San Francisco-based Ananya Health Inc. describes its development of a closed-loop cryoablation platform to freeze abnormal cells before they become cervical cancer. The company’s device achieves ablative temperatures without consumable gas, making the procedure portable, battery-powered, and ten times cheaper than traditional cryoablation.

Santa Ana Bio Inc. launched with combined series A and B rounds that pulled down $168 million for its precision immunology push in inflammatory diseases, with an aim of entering the clinic next year across several fronts.